Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
A Phase I safety and immunogenicity study with a three-component blood-stage malaria vaccine was conducted in adult male subjects living in an endemic area of Papua New Guinea. The preparations were recombinant proteins which corresponded to parts of the two merozoite surface proteins of Plasmodium falciparum (MSP1 and 2), and of the ring-infected erythrocyte surface antigen (RESA). The three proteins were emulsified with the adjuvant Montanide ISA720. Ten subjects were injected twice (four weeks apart) with the vaccine formulation and two with the adjuvant alone. Mild pain at the site of injection was reported by about half of the subjects but no systemic reaction related to the formulation occurred. There was a sharp rise in geometric mean stimulation index after the second dose compared to baseline for MSP1 and RESA, while the rise was small for MSP2. Geometric mean antibody titres increased for MSP1 during the study, whereas they hardly changed for MSP2 and RESA. The vaccine formulation was safe when used in an already immune population. The vaccine induced good cellular responses, especially for MSP1 and RESA. Boosting of humoral responses was weak, probably because of high baseline antibody levels.
Genton
B
B
Papua New Guinea Institute of Medical Research, Goroka and Maprik, Papua New Guinea. blaise.genton@chuv.hospvd.ch
Al-Yaman
F
F
Anders
R
R
Saul
A
A
Brown
G
G
Pye
D
D
Irving
D O
DO
Briggs
W R
WR
Mai
A
A
Ginny
M
M
Adiguma
T
T
Rare
L
L
Giddy
A
A
Reber-Liske
R
R
Stuerchler
D
D
Alpers
M P
MP
D000276:Adjuvants, Immunologic; D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis* / Q000276:immunology; D000953:Antigens, Protozoan / Q000276:immunology*; D016207:Cytokines / Q000097:blood; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007117:Immunization, Secondary; D017780:Malaria Vaccines / Q000009:adverse effects / Q000276:immunology*; D016778:Malaria, Falciparum / Q000517:prevention & control; D008297:Male; D008353:Mannitol / Q000031:analogs & derivatives / Q000276:immunology; D020066:Merozoite Surface Protein 1 / Q000276:immunology*; D008875:Middle Aged; D009829:Oleic Acids / Q000276:immunology; D010219:Papua New Guinea; D010963:Plasmodium falciparum / Q000254:growth & development / Q000276:immunology*; D015800:Protozoan Proteins / Q000276:immunology*; D012449:Safety; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination / Q000009:adverse effects
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016207:Cytokines; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D009829:Oleic Acids; D015800:Protozoan Proteins; C065974:merozoite surface protein 2, Plasmodium; C050256:ring-infected erythrocyte surface antigen (RESA), Plasmodium falciparum; C001681:mannide monooleate; D008353:Mannitol